EB-103

N/A

Report date: 2024/04/12 14:57:39

Base Information

Drug NameEB-103
Drug Alias NameEB-103
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsCentral Nervous System LymphomaLymphoma, AIDS-RelatedLymphoma, B-Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEstrella Biopharma IncEureka Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesEstrella Biopharma IncEureka Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCentral Nervous System LymphomaLymphoma, AIDS-RelatedLymphoma, B-Cell +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A